Company Eton Pharmaceuticals, Inc.

ETON

US29772L1089

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
3.21 ^USD	-2.13%		+2.23%	-26.71%

Apr. 17	Eton Pharmaceuticals, Inc. cancelled the transaction announced on April 15, 2024	CI
Apr. 15	Eton Pharmaceuticals, Inc. announced that it expects to receive $13.125 million in funding	CI

Eton Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing treatments for rare diseases. The Company has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.

Number of employees: 30

USD in Million	2022	Weight	2023	Weight	Delta
Prescription Drug Products 100.0 %	21	100.0 %	32	100.0 %	+48.90%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	21	100.0 %	32	100.0 %	+48.90%

Managers	Title	Age	Since
Sean Brynjelsen CEO	Chief Executive Officer	52	17-05-31
James Gruber DFI	Director of Finance/CFO	52	22-04-10
Lisa M. Wilson IRC	Investor Relations Contact	59	-
Danka Radosavljevic PRN	Corporate Officer/Principal	-	-
Scott Grossenbach SAM	Sales & Marketing	-	18-07-31
Ingrid Hoos LAW	General Counsel	-	-
David Krempa PRN	Corporate Officer/Principal	35	17-08-31
Kevin Guthrie PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Charles Casamento BRD	Director/Board Member	78	17-05-31
Paul Maier BRD	Director/Board Member	76	17-09-13
Norbert Riedel CHM	Chairman	66	17-09-06
Sean Brynjelsen CEO	Chief Executive Officer	52	17-05-31
Jenn Adams BRD	Director/Board Member	-	21-02-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	25,688,062	22,356,695 ( 87.03 %)	0	87.03 %

Name	Equities	%	Valuation
Opaleye Management, Inc. 9.848 %	2,529,887	9.848 %	9 M $
HARROW, INC. 7.716 %	1,982,000	7.716 %	7 M $
Sean Brynjelsen 4.185 %	1,074,940	4.185 %	4 M $
Vanguard Global Advisers LLC 4.001 %	1,027,688	4.001 %	4 M $
Westside Investment Management LLC 2.234 %	573,960	2.234 %	2 M $
Acuitas Investments LLC 1.915 %	492,054	1.915 %	2 M $
Paradigm Capital Management, Inc. 1.168 %	300,000	1.168 %	1 M $
BlackRock Institutional Trust Co. NA 1.094 %	281,006	1.094 %	1 M $
Bridgeway Capital Management LLC 0.9863 %	253,362	0.9863 %	950 108 $
Geode Capital Management LLC 0.8847 %	227,256	0.8847 %	852 210 $

Eton Pharmaceuticals, Inc.

21925 West Field Parkway Suite 235

60010-7278, Deer Park

http://www.etonpharma.com

address Eton Pharmaceuticals, Inc.(ETON)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.21 USD

Average target price

10 USD

Spread / Average Target

+211.53%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
ETON PHARMACEUTICALS, INC.	-26.71%	82.46M
MERCK KGAA	+5.73%	70.78B
KYOWA KIRIN CO. LTD.	+10.72%	9.15B
SK BIOPHARMACEUTICALS CO., LTD.	-15.34%	4.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+34.54%	4.22B
YUHAN CORPORATION	+5.09%	3.92B
INDIVIOR PLC	+27.76%	2.55B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.33%	2.24B
BETTA PHARMACEUTICALS CO., LTD.	-24.15%	2.26B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+6.23%	1.92B

Specialty & Advanced Pharmaceuticals